Investigational combination therapy CagriSema demonstrated significant weight reduction and noninferior HbA1c lowering in phase 3 clinical trials.

HealthDay News — For adults with type 2 diabetes receiving sodium-glucose cotransporter-2 (SGLT2) inhibitors, risk factors for ketoacidosis include high hemoglobin A1c, previous ketoacidosis, and ...

HealthDay News — High-frequency spinal cord stimulation significantly reduces pain and improves sensory function in people with painful diabetic neuropathy, according to a study published online ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.

Results from the final ORIGIN 3 analysis reveal that atacicept over 104 weeks significantly reduced the risk of a composite kidney disease progression event by 76% in adults with primary IgA ...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...

The sNDA approval provides clinicians with the first FDA-cleared photodynamic therapy for skin cancer, backed by phase 3 trial data demonstrating superior clinical and histologic clearance.

SAMA and SABA + SAMA use associated with increased risk for heart failure, arrhythmia, and mortality versus no use ...

Phase 3 COVER DFUS II trial data show the autologous therapy plus standard of care significantly improves wound closure rates at 12 weeks.

Labeling update reduces required post-infusion monitoring time for initial doses from 22 to 24 hours to 6 to 8 hours in patients with extensive-stage small cell lung cancer.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...

Biweekly enzyme replacement therapy demonstrates efficacy in pediatric and adult hypophosphatasia while offering lower injection frequency.